Caffeic acid phenethyl ester (CAPE) has been reported as a multifunctional compound. In this report, we tested the effect of CAPE and its derivatives on hepatitis C virus (HCV) replication in order to develop an effective anti-HCV compound. CAPE and CAPE derivatives exhibited anti-HCV activity against an HCV replicon cell line of genotype 1b with EC50 values in a range from 1.0 to 109.6 µM. Analyses of chemical structure and antiviral activity suggested that the length of the n-alkyl side chain and catechol moiety are responsible for the anti-HCV activity of these compounds. Caffeic acid n-octyl ester exhibited the highest anti-HCV activity among the tested derivatives with an EC50 value of 1.0 µM and an SI value of 63.1 by using the replicon cell line derived from genotype 1b strain Con1. Treatment with caffeic acid n-octyl ester inhibited HCV replication of genotype 2a at a similar level to that of genotype 1b irrespectively of interferon signaling. Caffeic acid n-octyl ester could synergistically enhance the anti-HCV activities of interferon-alpha 2b, daclatasvir, and VX-222, but neither telaprevir nor danoprevir. These results suggest that caffeic acid n-octyl ester is a potential candidate for novel anti-HCV chemotherapy drugs.
Citation: Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, et al. (2013) Inhibitory Effects of Caffeic Acid Phenethyl Ester Derivatives on Replication of Hepatitis C Virus. PLoS ONE 8(12): e82299. https://doi.org/10.1371/journal.pone.0082299
Editor: Hak Hotta, Kobe University, Japan
Received: September 15, 2013; Accepted: October 31, 2013; Published: December 17, 2013
Copyright: © 2013 Shen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by grants-in-aid from the Ministry of Health, Labor, and Welfare and from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Hepatitis C virus (HCV) is well known as a major causative agent of chronic liver disease including cirrhosis and hepatocellular carcinoma and is thought to persistently infect 170 million patients worldwide . HCV belongs to the genus Hepacivirus of the family Flaviviridae and possesses a viral genome that is characterized by a single positive strand RNA with a nucleotide length of 9.6 kb . The single polypeptide coded by the genome is composed of 3,000 amino acids and is cleaved by host and viral proteases, resulting in 10 proteins, which are classified into structural and nonstructural proteins . The viral genome is transcribed by a replication complex consisting of NS3 to NS5B and host factors . NS3 forms a complex with NS4A and becomes a fully active form to cleave the C-terminal parts of the nonstructural proteins. The advanced NS3/4A protease inhibitors, telaprevir and boceprevir, have been employed in the treatment of chronic hepatitis C patients infected with genotype 1 . Sustained virologic response (SVR) was reportedly 80% in patients infected with genotype 1 following triple combination therapy with pegylated interferon, ribavirin, and telaprevir , although the therapy exhibits side effects including rash, severe cutaneous eruption, influenza-like symptoms, cytopenias, depression, and anemia . In addition, there is the possibility of the emergence of drug-resistant viruses following treatment with those anti-HCV drugs  Thus, further study is required for development of safer and more effective anti-HCV compounds.
Several recent reports indicate that silbinin , epigallocatechin-3-gallate , curcumin , quercetin  and proanthocyanidins , which all originate from natural sources, have exhibited inhibitory activity against HCV replication in cultured cells. Caffeic acid phenethyl ester (CAPE) is an active component included in propolis prepared from honeybee hives, and has a similar structure to flavonoids (Fig. 1A). CAPE has multi-functional properties containing anti-inflammatory , antiviral , anticarcinogenic , and immunomodulatory activities . CAPE also inhibits enzymatic activities of endogenous and viral proteins – and transcriptional activity of NF-kappaB , . In addition, CAPE could suppress HCV replication enhanced by using the NF-kappaB activation activity of morphine , although it has been unknown which of moieties including CAPE is responsible for anti-HCV activity. Furthermore, it is not clear whether chemical modification of CAPE could enhance anti-HCV activity or not. In this report, we examined the effect of CAPE derivatives on HCV proliferation to develop more effective and safer anti-HCV compounds.
(A) Molecular structure of CAPE. (B) Huh7/Rep-Feo cells were incubated for 72 h in a medium containing various concentrations of CAPE. Luciferase and cytotoxicity assays were carried out by the method described in Materials and Methods. Error bars indicate standard deviation. The data represent results from three independent experiments. (C) Protein extract was prepared from Huh7/Rep-Feo cells treated for 72 h with the indicated concentration of CAPE and it was then was subjected to Western blotting using antibodies to NS3 and beta-actin.
Effect of CAPE on HCV RNA replication in HCV subgenomic replicon cells
CAPE is composed of ester of caffeic acid and phenethyl alcohol (Fig. 1A). We examined the effect of CAPE (compound 1) on both viral replication and cell growth in the HCV subgenomic replicon cell line Huh7/Rep-Feo. The replicon cell line was treated with various concentrations of compound 1. The replication level of the HCV RNA was measured as an enzymatic activity of luciferase, which is bicistronically, encoded on the replicon RNA. Compound 1 suppressed HCV RNA replication at concentrations from 1.3 to 40 µM in a dose-dependent manner, but did not affect cell viability (Fig. 1B). HCV NS3, which is a viral protease, was decreased at the protein level by treatment with CAPE in a dose-dependent manner, corresponding to the viral replication, whereas beta-actin was not changed in the replicon cell line (Fig. 1C). Based on the calculation using a dose dependency of CAPE, compound 1 exhibited an EC50 value of 9.0 µM and a CC50 value of 136.1 µM, giving a selectivity index estimate (SI) of 17.9 (Table 1). These results suggest that treatment with CAPE inhibits HCV replication in HCV subgenomic replicon cells.
Structure-activity relationship of CAPE analogues
To clarify the structure-activity relationship of CAPE analogues, we examined the effect of hydroxyl groups on the aromatic ring (catechol moiety), the alkenyl moieties on alpha, beta-unsaturated esters, and the ester parts as follows (Figure S1).
We tested whether commercially available CAPE-related compounds 2 to 6 (Fig. S1) affected HCV replication (Table 1). All these compounds showed weaker inhibitory activity than CAPE (1), but are not toxic. Compound 2, which is the acid component of CAPE, showed a slightly lower value of EC50 than compound 3, which is the compound 2 derivative replaced a hydroxyl group with a methoxyl group of catechol moiety, while compound 4, which is the derivative lacking two hydroxyl groups within catechol moiety, exhibits a higher value of EC50 than compounds 1 and 2. These data suggest that the catechol moiety of CAPE is required for anti-HCV activity. Interestingly, compounds 5 and 6, which are natural products including polyhydroxylated acid moieties in the ester parts, showed much weaker inhibitions than compound 1 and exhibits low Clog P values. The position of hydroxyl group or/and the structure of the ester part may affect the inhibitory activity and/or hydrophobicity.
We next examined the effects of caffeic acid ester compounds 7 to 11, which include various lengths of alkyl side chains, on HCV replication (Table 2 and Figure S2). The EC50 values decreased in the order methyl ester (compound 7), n-butyl ester (compound 8), n-hexyl ester (compound 9), and n-octyl ester (compound 10), suggesting that elongation of the n-alkyl side chain increased the inhibitory activity. However, the EC50 value of n-dodecyl ester (compound 11) was higher than that of compound 10. Thus, n-octyl ester (compound 10) showed the lowest EC50 value and the highest SI among the tested compounds shown in Tables 1 and 2. Compounds 7 to 11 gradually increased own Clog P values, corresponding to length of n-alkyl side chain (Fig. 2A). Compounds 10 and 11 exhibit EC50 values of 2.7 and 5.9 µM, respectively, SI values of 29.6 and 9.80, respectively, and Clog P values of 4.90 and 5.96, respectively, suggesting that high hydrophobic property of n-alkyl side chain decreases anti-HCV activity. The appropriate Clog P value of caffeic acid ester containing unsaturated side chain may be around 5.
Values of x-axis indicate EC50 values of CAPE analogues, while values of y-axis show Clog P values. (A) Correlation between the inhibitory effect on HCV replication and Clog P of CAPE analogues (Compound 7–11). (B) Correlation between the inhibitory effect on HCV replication and Clog P of CAPE analogues (Compound 10 and 13–16).
Dihydrocaffeic acid methyl ester (compound 12) showed less activity than caffeic acid methyl ester (compound 7) regardless of values of Clog P value and CC50, suggesting that the alpha, beta-unsaturated part attached to ester affects the anti-HCV activity level (Table 3 and Figure S3).
We further examined the effect of the hydroxyl groups on the aromatic ring on HCV replication (Table 4 and Figure S4). The EC50 values of O-methylated caffeic acid n-octyl esters (compounds 13 and 14) were higher than that of compound 10. Compounds 15 including 3, 4-di-O-methylated caffeic acid n-octyl ester exhibited higher EC50 than values of compounds 10, 13 and 14. However, addition of a third hydroxyl group to 3, 4, 5-trihydroxy derivative (compound 16) of compound 10 resulted in a reduction of anti-HCV activity. Furthermore, Clog P values of compound 10, 13, 14, 15 and 16 were not correlated with anti-HCV activity (EC50 value) (Fig. 2B). These results suggest that the catechol moiety plays an important role in anti-HCV activity, and that the 4-hydroxy moiety is more important for the activity than the 3-hydroxy moiety.
Thus, compound 10, which exhibits the lowest EC50 value and the highest SI value, is the most effective compound among CAPE analogues used in this study.
Effect of CAPE derivatives on virus production
The structure of compound 10 is shown in Fig. 3A. Treatment with compound 10 reduced HCV replication and NS3 protein in a dose-dependent manner at a higher anti-HCV level than compound 1 (Figs. 3B and C), but not effect enzymatic activities of firefly and Renilla luciferases (Fig. 3D) and IRES-dependent translation (Fig. 3E), suggesting that inhibition of HCV replication by compound 10 is not due to offtarget effect. We evaluated the inhibitory effect of compound 10 on three different subgenomic replicon cell lines (1b: N strain, Con1 strain, 2a: JFH-1 strain) and one full genome replicon cell line (1b: O strain). Compound 10 inhibited the viral replication of all replicon cell lines at similar level, and exhibited the lowest EC50 value of 1.0 µM and an SI value of 63.1 by using Con1 replicon cells (Table 5). We next examined the effect of compound 10 on virus production by using HCVcc, since subgenomic replicon mimics HCV replication, but not the whole viral cycle. The Huh7 OK1 cell line, which is highly permissive to the HCV JFH1 strain , was infected with HCVcc and then treated with compound 10 at 24 h post-infection. The supernatant was harvested 72 h post-infection from the culture supernatant and then the RNA that prepared from the supernatant was estimated by real time qRT-PCR. Figure 3F shows that treatment with compound 10 reduced HCV viral production (EC50 = 1.8±0.4 µM) in a similar way to the data obtained by using a replicon cell line. To clarify whether or not compound 10 inhibited HCV replication via interferon-signaling pathway, we analyzed ISRE activity and the expression of interferon stimulated gene (ISG) by using reporter assay and RT-PCR, respectively. The replicon cells were harvested at 48 h post-treatment. There were no significant effects of compound 1, 6 and 10 on ISRE-promoter activities, while interferon alpha 2b significantly enhanced it as a positive control (Fig.4 A). The data of the RT-PCR analysis showed that the transcriptional expressions of ISGs including Mx1, MxA, IFIT4, ISG15, OAS1, OAS2, and OAS3 were induced with interferon alpha 2b, but not with compound 1, 6 and 10 (Fig. 4B). These data suggest that the CAPE derivatives have an inhibitory effect on virus production and replication, irrespective of interferon signaling induction.
(A) Molecular structure of compound 10. (B) Huh7/Rep-Feo cells were incubated for 72 h in a medium containing various concentrations of compound 10. Luciferase and cytotoxicity assays were carried out by the method described in Materials and Methods. Error bars indicate standard deviation. The data represent three independent experiments. (C) Protein extract was prepared from Huh7/Rep-Feo cells treated for 72 h with the indicated concentration of compound 10 and it was then subjected to Western blotting using antibodies to NS3 and beta-actin. (D) Huh7 cell line was transfected with pEF Fluc IN encoding firefly luciferase or pEF Rluc IN encoding Renilla luciferase. Both transfected cell lines were incubated with DMSO (Control) or 40 µg/ml compound 10. Firefly or Renilla luciferase activity was measured 72 h post-treatment. Luciferase activity was normalized with protein concentration. Error bars indicate standard deviation. The data were represented from three independent experiments. (E) Schematic structure of RNA transcribed from the plasmids was shown (Top). The bicistronic gene is transcribed under the control of elongation factor 1α (EF1α) promoter. The upstream cistron encoding Renilla luciferase (RLuc) is translated by a cap-dependent mechanism. The downstream cistron encodes the fusion protein (Feo), which consists of the firefly luciferase (Fluc) and neomycin phosphotransferase (Neor), and is translated under the control of the EMCV or HCV IRES. Huh7 cell line was transfected with each plasmid and incubated for 72 h post-treatment with DMSO (control) or 40 µg/ml of compound 10. Firefly and Renilla luciferase activities were measured. Relative ratio of Firefly luciferase activity to Renilla luciferase activity was represented as percentage of the control condition. Error bars indicate standard deviation. The data were represented from three independent experiments. (F) Huh7 OK1 cell line was infected with HCVcc derived from JFH-1 strain and then treated with several concentrations of compound 10 at 24 h post-infection. The resulting cells were harvested 72 h post-infection. The viral RNA of supernatant was purified and estimated by the method described in Materials and Methods. Error bars indicate standard deviation. The data represent three independent experiments. Treatment with DMSO corresponds to ‘0’.
(A) Plasmids pISRE-TA-Luc and phRG-TK were co-transfect into Huh7 OK1 cells. The transfected cells were cultured with 1, 10, 100, or 1000 U/mL of interferon-alpha 2b, and compounds 1, 6 and 10. Treatment with DMSO corresponds to ‘0’. After 48 h of treatment, luciferase activities were measured, and the value were normalized against Renilla luciferase activities. Error bars indicate standard deviation. The data represent three independent experiments. (B) Huh7 replicon cell line of genotype 1b was treated with 1, 10, 100, or 1000 U/mL of interferon-alpha 2b, and compounds 1, 6 and 10 for 48 h. Treatment with DMSO corresponds to the control. The mRNAs of Mx1, MxA, IFIT4, ISG15, OAS1, OAS2, OAS3, and GAPDH as an internal control were detected by RT-PCR.
Synergistic effect of caffeic acid n-octyl ester on interferon and direct-acting antiviral agents
To estimate the effects of drug combinations on anti-HCV activity, we examined the antiviral activity of compound 10 in combination with IFN-α 2b, telaprevir (NS3 protease inhibitor), danoprevir (NS3 protease inhibitor), daclatasvir (NS5A inhibitor) or VX-222 (NS5B polymerase inhibitor). Con1 LUN Sb #26 replicon cells were treated with compound 10 in combination with each anti-HCV agent at various concentration rations for 72 h. The effect of each drug combination on HCV replication was analyzed by using CalcuSyn. An explanatory diagram of isobologram was shown at a right end of lower panels of Fig. 5A as described in Materials and Methods. As shown in the resulting isobologram, all plots of the calculated EC90 values of compound 10 with IFN-alpha 2b, daclatasvir, or VX-222 are located under the additive line, while the plots of compound 10 with telaprevir, or danoprevir are located above the additive line and closed to the additive line (Fig. 5A). Additionally, we determined the degree of inhibition for each drug combination was analyzed as the combination index (CI) calculation at 50, 75 and 90% of effective concentrations by using CalcuSyn. An explanatory diagram was shown at a right end of lower panels of Fig. 5B as described in Materials and Methods. On the basis of the CalcuSyn analysis, the combination of compound 10 with daclatasvir exhibited strong synergistic effect on inhibition of HCV replication in the replicon cells (Fig. 5B, upper middle). The combination of compound 10 with VX-222 exhibited an additive to synergistic effect, suggesting that it trends toward synergistic (Fig. 5B, upper right), and with IFN-alpha 2b exhibited an antagonistic to synergistic effect, suggesting that it trends toward synergistic (Fig. 5B, upper left). In contrast, the combination of compound 10 with telaprevir resulted in antagonistic effect (Fig. 5B, lower left), and with danoprevir resulted in an antagonistic to additive effect, suggesting it trends toward antagonistic (Fig. 5B, lower middle). These calculated data of combination tests suggest that daclatasvir, IFN-alpha 2b, and VX-222 synergistically, but telaprevir and danoprevir antagonistically, inhibit HCV replication in combination with compound 10.
The Huh7 cell line, including the subgenomic replicon RNA of genotype 1b strain Con1, was treated for 72h with combinations of compound 10 and IFN-α 2b, daclatasvir, VX-222, telaprevir, or danoprevir. Luciferase assay were carried out as described in Materials and Methods. (A) The calculated EC90 values for combination were plotted as the fractional concentration (FC) of compound 10 and one of IFN-α 2b, daclatasvir, VX-222, telaprevir, and danoprevir on the x and y axes, respectively. Synergy, antagonism and additivity are indicated in a representative graph as a right end of lower graphs and are described in Materials and Methods. (B) Combination indexes of compound 10 with IFN-α 2b, daclatasvir, VX-222, telaprevir, or danoprevir at the EC50, EC75, and EC90 values were measured at various drug rations. Synergy, antagonism and additivity are indicated in a representative graph as a right end of lower graphs and are described in Materials and Methods.
CAPE is an active component of propolis, which possesses broad-spectrum biological activities –. In this study, CAPE suppressed HCV RNA replication in a dose-dependent manner (Fig. 1A and B). Treatment with CAPE inhibited HCV replication with an EC50 of 9.0 µM and an SI of 17.9 in Huh7/Rep-Feo cells (Table 1). The treatment of the replicon cell line with CAPE did not induce expression of the IFN-inducible gene (Fig. 4), suggesting that the inhibition of HCV replication by CAPE is independent of the IFN signaling pathway.
We also examined the effect of CAPE derivatives on HCV replication. Our data suggest that the n-alkyl side chain and catechol moiety of the CAPE derivative are critical in its anti-HCV activity (Tables 2 and 3). The EC50 value of the derivative decreased dependently on the length of the n-alkyl side chain until reaching octyl ester length (Table 2), while longer chains than octyl ester of a derivative led to an increase in the EC50 value and Clog P value. Compound 10, Caffeic acid n-octyl ester, exhibited the highest anti-HCV activity among the tested compounds with an EC50 value of 2.7 µM and an SI value of 26.6. Cyclosporine A and its analogues could suppress the viral replication of genotype 1b at a higher level than that of genotype 2a . Interestingly, compound 10 could inhibit HCV replication of genotype 1b and 2a at a similar level, irrespective of expression of the interferon-inducible gene (Fig. 4). CAPE and its derivatives may therefore possess a mechanism different from cyclosporine A and its analogues with respect to anti-HCV activity.
CAPE has been reported to be an inhibitor of NF-kappaB , . Lee et al. reported that the catechol moiety in CAPE was important for inhibition of NF-kappaB activation . The data shown in Table 3 suggest that the catechol moiety in CAPE is critical to the anti-HCV activity of compound 10. Previous studies have implicated the inhibition of NF-kappaB in anti-HCV activity. Treatment with an extract prepared from Acacia confusa  or San-Huang-Xie-Xin-Tang  could suppress HCV replication and inhibit NF-kappaB activation. However, Chen et al. reported that curcumin-mediated inhibition of NF-kappaB did not contribute to anti-HCV activity . Furthermore, treatment with N′-(Morpholine-4carbonyloxy)-2(naphthalene-1-yl) acetimidamide could activate NF-kappaB and downstream gene expression in the same Huh7/Rep-Feo replicon cell line as the cell line used in this study and exhibited potent inhibition of HCV replication without interferon signaling . These reports support the notion that CAPE derivatives do not mainly target NF-kappaB activity as part of their anti-HCV activity.
Several host proteins have been reported to regulate function of NS5A, leading to supporting HCV replication (review in ,  ). Daclatasvir exhibited potent synergistic effect on anti-HCV activity in combination of compound 10 (Fig. 5). Anti-HCV activity of compound 10 might associate with intrinsic functions of host factors that interact with NS5A. NS3 protease inhibitors exhibited antagonistic effect in combination of compound 10 (Fig. 5). The inhibitory effect of compound 10 might be mediated by the activation of an unknown endogenous protease that is nonspecifically suppressed by NS3 protease inhibitors. Further study to clarify the mechanism by which compound 10 suppresses HCV replication might contribute to identification of a novel host factor as a drug target for development of the effective compound supporting an effect of other anti-HCV drugs.
In conclusion, we showed that CAPE and its analogue possess a significant inhibitory effect against HCV replication. The length of n-alkyl side chains and the catechol moiety of CAPE are critical to its inhibitory activity against HCV replication. The most effective derivative among the tested compounds was caffeic acid n-octyl ester, which exhibited an EC50 value of 1 µM and an SI value of 63.1 in the replicon cell line of genotype 1b strain Con1. Treatment with caffeic acid n-octyl ester reduced the viral replication of genotype 1b and 2a at a similar level and inhibited viral production of HCVcc. Treatment with caffeic acid n-octyl ester could synergistically enhance the anti-HCV activities of IFN-α 2b, daclatasvir, and VX-222, but neither telaprevir nor danoprevir. Further investigation to clarify the mechanism of anti-HCV activity and further modification of the compound to improve anti-HCV activity will lead to novel therapeutic strategies to treat chronic hepatitis C virus infection.
Materials and Methods
Boldface numbers in this text indicate the compound numbers shown in Tables. All chemical structures of compounds used in this study are shown in figure S1. CAPE (1), caffeic acid (2), ferulic acid (3), and chlorogenic acid (5) and were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cinnamic acid phenethyl ester (4) was from Tokyo Chemical Industry (Tokyo, Japan). Rosmarinic acid (6) was from Wako Pure Chemical (Tokyo, Japan). Caffeic acid n-octyl ester (n-octyl caffeate) (10), 3-O-methylcaffeic acid n-octyl ester (n-octyl-3-methylcaffeate) (13), 4-O-methylcaffeic acid n-octyl ester (n-octyl-3-methylcaffeate) (14), and 3, 4-O-dimethylcaffeic acid n-octyl ester (n-octyl-3, 4-methylcaffeate) (15) were from LKT Laboratories (St. Paul, MN, USA).
Caffeic acid esters 7, 8, 9, and 11 were synthesized by preparing caffeic acid chloride followed by treatment with corresponding alcohols . Dihydrocaffeic acid ester 12 was prepared by hydrogenation of 7. Compound 16 is a newly synthesized ester. Spectroscopic data of known esters 7–9, and 11 prepared here were identical to those reported - Interferon alfa-2b (IFN-α 2b) was obtained from MSD (Tokyo, Japan). Telaprevir and daclatasvir were purchased from Selleckchem (Houston, TX, USA). Danoprevir and VX-222 were from AdooQ BioScience (Irvine, CA, USA).
Chemistry of 3,4,5-Trihydroxycinnamic acid n-octyl ester
3,4,5-Trihydroxycinnamic acid n-octyl ester (16) was prepared by condensation of corresponding benzaldehydes with malonic acid n-octyl monoester . A solution of malonic acid n-octyl monoester (432 mg, 2 mmol), 3,4,5-trihydroxybenzaldehyde (462 mg, 3 mmol) and piperidine (0.2 mL) in pyridine (2 mL) was heated at 70°C for 1 h. The reaction mixture was concentrated under a vacuum to give a residue, which was dissolved in CHCl3-IPA (3∶1, v/v) and then washed with 10% HCl and water. The organic layer was dried over Na2SO4 and evaporated to give a residue, which was purified by silica gel column chromatography using AcOEt-hexane (1∶1, v/v) as eluent to give the corresponding n-octyl ester (85 mg, 13.8%) as a pale powder. FT-IR νmax (KBr): 3389, 3239, 2923, 1675, 1627, 1606 cm−1. 1H NMR (400MHz, CD3OD) δ: 0.86 (3H, t, J = 7.2 Hz), 1.20–1.40 (10H, m), 1.65 (2H, quintet, J = 6.4 Hz), 4.11, (2H, t, J = 6.4 Hz), 6.16 (2H, d, J = 15.6 Hz), 6.55 (2H, s), 7.40 (2H, d, J = 15.6 Hz). 13C NMR (100 Hz, CD3OD) δ: 14.4, 23.7, 27.1, 29.8, 30.3, 30.4, 32.9, 65.6, 108.5, 115.3, 126.6, 137.5, 147.1, 169.4. CI MS m/z: 309 (M++H). High-resolution CI MS calcd. for C17H25O5 (M++H) for 309.1702. Found: 309.1686.
Replicon cell lines and virus infection
The Huh7/Rep-Feo cell line, which harbors the subgenomic replicon RNA composed of HCV IRES, the gene of the fusion protein consisting of neomycin phosphotransferase and firefly luciferase, EMCV IRES and a nonstructural gene of genotype 1b strain N in order in Huh7 cell line, was previously established . Thus, the luciferase activity corresponds to the level of HCV RNA replication. The cell line was maintained in Dulbecco's modified Eagle medium containing 10% fetal calf serum and 0.5 mg/mL G418 and cultured in absence of G418 when they were treated with compounds. The Lunet/Con1LUN Sb #26 cell line, which harbors the subgenomic replicon RNA of the Con1 strain (genotype 1b), was described previously . The OR6 cell line, which harbors the full genomic replicon RNA of the O strain (genotype 1b), was described previously . The HCV replicon cell line derived from the genotype 2a strain JFH1 was described previously . The viral RNA derived from the plasmid pJFH1 was transcribed and introduced into Huh7OK1 cells according to the method of Wakita et al. . The virus was amplified by the several times passages. The cells were infected with the virus at a multiplicity of infection (moi) of 1 and then treated with each compound at 24 h post-infection. The culture supernatants were harvested 72 h post-treatment to estimate the viral RNA as described below.
Determination of luciferase activity in HCV replicon cells
The replicon cells were seeded at 2×104 cells per well in a 48-well plate 24 h before treatment. Compounds were added to the culture medium to give various concentrations. The resulting cells were harvested 72 h post-treatment and lysed with cell culture lysis reagent (Promega, Madison, WI). The luciferase activity of each cell lysate was estimated using a luciferase assay system (Promega). The resulting luminescence was detected by a Luminescencer-JNR AB-2100 (ATTO, Tokyo, Japan).
Determination of Cytotoxicity in HCV replicon cells
The replicon cells were seeded at a density of 1×104 cells per well in a 96-well plate and then incubated at 37°C for 24 h. Compounds were added to the culture medium to give various concentrations and were then harvested 72 h post-treatment. Cell viability was measured using a dimethylthiazol carboxymethoxy-phenylsulfophenyl tetrazolium (MTS) assay with a CellTiter 96 aqueous one-solution cell proliferation assay kit (Promega).
Western blotting was carried out by the method described previously . The antibodies to NS3 (clone 8G-2, mousemonoclonal, Abcam, Cambridge, UK), and beta-actin were purchased from Cell Signaling Technology (rabbit polyclonal, Danvers, MA, USA) and were used as the primary antibodies in this study.
Total RNAs were prepared from cells by using the RNAqueous-4PCR kit (Life Technologies, Carlsbad, CA). Viral RNA were prepared from culture supernatants by using the QIAamp Viral RNA mini kit (QIAGEN, Hilden, Germany). The viral RNA genome was estimated by the qRT-PCR method described previously . RT-PCR was carried out by the method described previously  which was slightly modified at the PCR step. The PCR samples were incubated once for 10 min at 95°C for an initial activation step of the AmpliTaq Gold DNA Polymerase (Life Technologies), and then subjected to an amplification step of 30 repeats of the cycle consisting of three segments as follow: 0.5 min at 95°C, 1 min at 55°C and 1 min at 72°C. The primers used in this study were as follows: Mx1: 5′-AGCCACTGGACTGACGACTT-3′ and 5′-GAGGGCTGAAAATCCCTTTC-3′;
MxA: 5′-GTCAGGAGTTGCCCTTCCCA-3′ and 5′-ATTCCCATTCCTTCCCCGG-3′;
IFIT4: 5′-CCCTTCAGGCATAGGCAGTA-3′ and 5′-CTCCTACCCGTCACAACCAC -3′; ISG15: 5′-CGCAGATCACCCAGAAGAT-3′ and 5′-GCCCTTGTTATTCCTCACCA-3′;
OAS1: 5′-CAAGCTCAAGAGCCTCATCC-3′ and 5′-TGGGCTGTGTTGAAATGTGT-3′;
OAS2: 5′-ACAGCTGAAAGCCTTTTGGA-3′ and 5′-GCATTAAAGGCAGGAAGCAC-3′;
OAS3: 5′-CACTGACATCCCAGACGATG-3′ and 5′-GATCAGGCTCTTCAGCTTGGC-3′;
GAPDH: 5′-GAAGGTGAAGGTCGGAGTC and 5′- GAAGATGGTGATGGGATTTC-3′
Effects on activities of internal ribosome entry site (IRES) and luciferases
Huh7 OK1 cells were transfected with pEF.Rluc.HCV.IRES.Feo or pEF.Rluc.EMCV.IRES.Feo . These transfected cells were seeded at 2×104 cells per well in a 48-well plate 24 h before treatment, treated with DMSO or compound 10, and then harvested at 72 h post-treatment. The firefly luciferase activities were measured with a luciferase assay system (Promega). The total protein concentration was measured using the BCA Protein Assay Reagent Kit (Thermo Scientific, Rockford, IL, USA) to normalize luciferase activity. To evaluate the interferon response, Huh7OK1 cells were seeded on a 48 well plate at a density of 2×104 cells per well, and transfected with pISRE-TA-Luc (Takara bio, Shiga, Japan) and phRG-TK (Promega). These transfected cells were incubated in the presence of compounds, IFN-α 2b, or DMSO, and then harvested at 48 h post-treatment. The firefly luciferase and Renilla luciferase activities were quantified by using Dual luciferase reporter assay system (Promega).
Prediction of ClogP for compounds
The ClogP value deduced from chemical structure roughly corresponds to a value of hydrophobicity. The ClogP values of compounds used in this study were calculated using the computer software Chem Bio Office Ultra 2008 (PerkinElmer, Cambridge, MA, USA).
Synergistic effect of caffeic acid n-octyl ester on anti-HCV activities of other drugs
The effects of drug-drug combinations were evaluated by using the Con1 LUN Sb #26 replicon cells, and were analyzed by using the computer software CalcuSyn (Biosoft, Cambridge, United Kingdom). Dose inhibition curves of two different drugs were plotted with each other. In each drug combination, EC90 values of several combinations of two different drugs were plotted as the fractional concentration (FC) of both drugs on the x and y-axes. Additivity indicates the line linked between 1.0 FC value points of both drugs in the absence of each other. Synergy and antagonism are indicated by values plotted under and above, respectively, an additivity line. The explanatory diagram of isobologram is shown in a right end of lower panels of Figure 5A. Combination indexes (CIs) were calculated at the EC50, EC75, and EC90 by using CalcuSyn. A CI value of less than 0.9 indicates synergy. A CI value ranging from 0.9 to 1.1 indicates additivity. A CI value of more than 1.1 indicates antagonism. The explanatory diagram was shown in a right end of lower panels of Figure 5B.
Molecular structure of CAPE and commercial CAPE-related compounds. CAPE structure is divided into three parts: (I) the catechol moiety, (II) the alkenyl moiety on alpha, beta -unsaturated ester, and (III) the ester part. Molecular structures of CAPE and its commercial derivatives are shown.
The basic structure and side moieties of compounds shown in Table 2. Each compound structure is represented on the basis of the basic structure (top).
The molecular structures of compounds 7 and 12, which are shown in Table 3. Both compounds are different in alpha, beta-unsaturated or saturated part attached to ester.
Conceived and designed the experiments: MT KM. Performed the experiments: H. Shen AY MN HY MS H. Shindo SM. Analyzed the data: HK TT NE. Contributed reagents/materials/analysis tools: YF MI NK NS. Wrote the paper: H. Shen AY MT KM.
- 1. Baldo V, Baldovin T, Trivello R, Floreani A (2008) Epidemiology of HCV infection. Curr Pharm Des 14: 1646–1654.
- 2. Moriishi K, Matsuura Y (2012) Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol 3: 54.
- 3. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K (1991) Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 88: 5547–5551.
- 4. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, et al. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110–113.
- 5. Hofmann WP, Zeuzem S (2011) A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8: 257–264.
- 6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405–2416.
- 7. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 Suppl 1S88–100.
- 8. Kieffer TL, Kwong AD, Picchio GR (2010) Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 65: 202–212.
- 9. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, et al. (2010) Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 138: 1112–1122.
- 10. Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, et al. (2012) (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55: 720–729.
- 11. Chen MH, Lee MY, Chuang JJ, Li YZ, Ning ST, et al. (2012) Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT. Int J Mol Med 30: 1021–1028.
- 12. Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, et al. (2012) Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat 19: e81–88.
- 13. Takeshita M, Ishida Y, Akamatsu E, Ohmori Y, Sudoh M, et al. (2009) Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem 284: 21165–21176.
- 14. Toyoda T, Tsukamoto T, Takasu S, Shi L, Hirano N, et al. (2009) Anti-inflammatory effects of caffeic acid phenethyl ester (CAPE), a nuclear factor-kappaB inhibitor, on Helicobacter pylori-induced gastritis in Mongolian gerbils. Int J Cancer 125: 1786–1795.
- 15. Ho CC, Lin SS, Chou MY, Chen FL, Hu CC, et al. (2005) Effects of CAPE-like compounds on HIV replication in vitro and modulation of cytokines in vivo. J Antimicrob Chemother 56: 372–379.
- 16. Chiao C, Carothers AM, Grunberger D, Solomon G, Preston GA, et al. (1995) Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. Cancer Res 55: 3576–3583.
- 17. Boudreau LH, Maillet J, LeBlanc LM, Jean-Francois J, Touaibia M, et al. (2012) Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes. PLoS One 7: e31833.
- 18. Lee KW, Chun KS, Lee JS, Kang KS, Surh YJ, et al. (2004) Inhibition of cyclooxygenase-2 expression and restoration of gap junction intercellular communication in H-ras-transformed rat liver epithelial cells by caffeic acid phenethyl ester. Ann N Y Acad Sci 1030: 501–507.
- 19. Fesen MR, Kohn KW, Leteurtre F, Pommier Y (1993) Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A 90: 2399–2403.
- 20. Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB (1996) Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A. 93: 9090–9095.
- 21. Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, et al. (2003) Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 163: 1167–1175.
- 22. Okamoto T, Omori H, Kaname Y, Abe T, Nishimura Y, et al. (2008) A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J Virol 82: 3480–3489.
- 23. Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, et al. (2006) Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 80: 4510–4520.
- 24. Lee Y, Shin DH, Kim JH, Hong S, Choi D, et al. (2010) Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. Eur J Pharmacol 643: 21–28.
- 25. Lee JC, Chen WC, Wu SF, Tseng CK, Chiou CY, et al. (2011) Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2. Antiviral Res 89: 35–42.
- 26. Lee JC, Tseng CK, Wu SF, Chang FR, Chiu CC, et al. (2011) San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression. J Viral Hepat 18: e315–324.
- 27. Kusano-Kitazume A, Sakamoto N, Okuno Y, Sekine-Osajima Y, Nakagawa M, et al. (2012) Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. Antimicrob Agents Chemother 56: 1315–1323.
- 28. Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5: 453–463.
- 29. Lee YJ, Liao PH, Chen WK, Yang CY (2000) Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells. Cancer Lett 153: 51–56.
- 30. Bourne GT, Golding SW, McGeary RP, Meutermans WD, Jones A, et al. (2001) The development and application of a novel safety-catch linker for BOC-based assembly of libraries of cyclic peptides. J Org Chem 66: 7706–7713.
- 31. Nagaoka T, Banskota AH, Tezuka Y, Saiki I, Kadota S (2002) Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26-L5 carcinoma cell line. Bioorg Med Chem 10: 3351–3359.
- 32. Uwai K, Osanai Y, Imaizumi T, Kanno S, Takeshita M, et al. (2008) Inhibitory effect of the alkyl side chain of caffeic acid analogues on lipopolysaccharide-induced nitric oxide production in RAW264.7 macrophages. Bioorg Med Chem 16: 7795–7803.
- 33. Zhang Z, Xiao B, Chen Q, Lian XY (2010) Synthesis and biological evaluation of caffeic acid 3,4-dihydroxyphenethyl ester. J Nat Prod 73: 252–254.
- 34. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, et al. (2003) Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4: 602–608.
- 35. Frese M, Barth K, Kaul A, Lohmann V, Schwarzle V, et al. (2003) Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. Journal of General Virology 84: 1253–1259.
- 36. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, et al. (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 329: 1350–1359.
- 37. Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, et al. (2010) Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. J Gastroenterol 45: 523–536.
- 38. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791–796.
- 39. Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, et al. (2012) Inhibition of hepatitis C virus replication and NS3 helicase by the extract of the feather star Alloeocomatella polycladia. Mar Drugs 10: 744–761.
- 40. Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, et al. (2012) Inhibition of Both Protease and Helicase Activities of Hepatitis C Virus NS3 by an Ethyl Acetate Extract of Marine Sponge Amphimedon sp. PLoS One 7: e48685.
- 41. Jin H, Yamashita A, Maekawa S, Yang PT, He LM, et al. (2008) Griseofulvin, an oral antifungal agent, suppresses hepatitis C virus replication in vitro. Hepatology Research 38: 909–918.